Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay
Authors:
- 1 January 2008
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 67 (1) , 84-90
Abstract
Objective: To analyse the performance of a new M tuberculosis-specific interferon γ (IFNγ) assay in patients with chronic inflammatory diseases who receive immunosuppressive drugs, including tumour necrosis factor α (TNFα) inhibitors. Methods: Cellular immune responses to the M tuberculosis-specific antigens ESAT-6, CFP-10, TB7.7 were prospectively studied in 142 consecutive patients treated for inflammatory rheumatic conditions. Results were compared with tuberculin skin tests (TSTs). Association of both tests with risk factors for latent M tuberculosis infection (LTBI) and BCG vaccination were determined and the influence of TNFα inhibitors, corticosteroids, and disease modifying antirheumatic drugs (DMARDs) on antigen-specific and mitogen-induced IFNγ secretion was analysed. Results: 126/142 (89%) patients received immunosuppressive therapy. The IFNγ assay was more closely associated with the presence of risk factors (odds ratio (OR) = 23.8 (95% CI 5.14 to 110) vs OR = 2.77 (1.22 to 6.27), respectively; p = 0.009), but less associated with BCG vaccination than the TST (OR = 0.47 (95% CI 0.15 to 1.47) vs OR = 2.44 (0.74 to (8.01), respectively; p = 0.025). Agreement between the IFNγ assay and TST results was low (κ = 0.17; 95% CI 0.02 to 0.32). The odds for a positive IFNγ assay strongly increased with increasing prognostic relevance of LTBI risk factors. Neither corticosteroids nor conventional DMARDs significantly affected IFNγ responses, but the odds for a positive IFNγ assay were decreased in patients treated with TNFα inhibitors (OR = 0.21 (95% CI 0.07 to 0.63), respectively; p = 0.006). Conclusions: These results demonstrate that the performance of the M tuberculosis antigen-specific IFNγ ELISA is better than the classic TST for detection of LTBI in patients receiving immunosuppressive therapy for treatment of systemic autoimmune disorders.Keywords
This publication has 27 references indexed in Scilit:
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosisAnnals of the Rheumatic Diseases, 2005
- Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor AntagonistsClinical Infectious Diseases, 2004
- High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapyClinical Gastroenterology and Hepatology, 2004
- Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapyArthritis & Rheumatism, 2004
- Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active‐surveillance reportArthritis & Rheumatism, 2003
- Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementThe Lancet Infectious Diseases, 2003
- Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α–neutralizing agentsArthritis & Rheumatism, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Diagnostic Standards and Classification of Tuberculosis in Adults and Children: This Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention was Adopted by the ATS Board of Directors, July 1999. This Statement was endorsed by the Council of the Infectious Disease Society of America, September 1999American Journal of Respiratory and Critical Care Medicine, 2000